Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company whose mission is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, announces the establishment of its shareholders ‘ club, known as The HQ of the Shareholders. This club was inaugurated on may 18, 2017 at an event organized by Biotech Agora.
Boost your gains
Free and open to all, holders of bearer shares or registered holders of a share of the company, the HQ of the Shareholders Quantum Genomics has the ambitious aim of promoting the knowledge, by the nearly 5,000 shareholders today at its capital, to the life of the company, its activity, its R&D programs, or its strategy.
Take advantage of the benefits offered to the members of the Shareholders Club Quantum Genomics
The registration in the Shareholders ‘ Club is to be made directly online, on the internet site www.quantum-genomics.com, tab Investors, section HQ of the Shareholders.
The members of the HQ of the Shareholders Quantum Genomics will benefit from the following advantages :
receiving the information in real-time : press releases, annual reports, letter to the shareholders club, documentation for general meetings, etc ;
meetings with the leaders of Quantum Genomics, on the occasion of meetings reserved to the members of the HQ of the Shareholders ;
permanent contact with the management committee, through the e-mail address dedicated :
QG-Actionnaires@quantum-genomics.com.
Lionel Ségard, Chairman and ceo of Quantum Genomics, says :
“Quantum Genomics has, since its ipo on Alternext Paris in 2014 in a close, trusting relationship with its shareholders. It is to strengthen this relationship and respond in particular to the expectations of individual investors concerning the transparency and availability of information as Quantum Genomics has decided to establish the HEADQUARTERS of Shareholders, which will thus enable us to multiply the opportunities for interaction with our shareholders. ”
ABOUT QUANTUM GENOMICS
Quantum Genomics is a biopharmaceutical company whose mission is to develop new therapies for unmet medical needs in the field of cardiovascular diseases, including high blood pressure and congestive heart failure.
Quantum Genomics is developing a new therapeutic approach based on inhibition of Aminopeptidase A in the brain (BAPAI – Brain Aminopeptidase A Inhibition), the result of more than twenty years of research in the laboratory “Central Neuropeptides and the Regulation of Fluid and Cardiovascular” (Collège de France, INSERM, CNRS, Université Paris Descartes), directed by Dr. Catherine Llorens-Cortes. This laboratory is associated with Quantum Genomics through a joint laboratory public/private, baptized CARDIOBAPAI, accredited by the French National Research Agency (ANR) since 2015.
Quantum Genomics, based in Paris and New York, is listed on the Alternext market in Paris (FR0011648971 – ALQGC).
Boost your gains